GLPwatch
What are the cardiovascular effects of the newer classes of drugs for type 2 diabetes?
JAAPA · 2018
Last updated 2026-05-28Research on newer diabetes drugs found that two medications, empagliflozin and liraglutide, improved cardiovascular outcomes in people with type 2 diabetes. These results come from five trials that specifically examined heart-related effects of these drugs.
AI summary of the abstract below.
| Journal | JAAPA, 2018 |
|---|---|
| Citations | 0 |
| Relative citation ratio | 0.00 |
| NIH percentile | 0 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes, Cardiovascular Risk Reduction |
Abstract
New classes of drugs to treat type 2 diabetes are continually being developed and marketed. The FDA has issued guidance to the pharmaceutical industry that newer hypoglycemic agents should not be associated with unacceptable increases in cardiovascular risk. To date, five trials have assessed specific cardiovascular endpoints for these newer agents. Empagliflozin and liraglutide have been found to improve cardiovascular outcomes.
Verbatim abstract via PubMed 29470367 ↗